Related Experiment Videos
Phase II trials of methylglyoxal-bis (guanylhydrazone)
Abstract:
Broad phase II trial of methylglyoxal-bi (guanylhydrazone) (MGBG) is under way at the Memorial Sloan-Kettering Cancer Center. Studies in renal cell carcinoma, lymphomas, and non-small-cell lung cancer are completed, and substantial numbers of patients with esophageal and head and neck cancer have been treated. Small numbers of patients with other solid tumors have also been entered into the study. MGBG has significant antineoplastic activity against lymphomas, with 16/40 heavily pretreated patients (40%) having partial remissions (PR) lasting 1 to 8+ months. MGBG has also demonstrated more modest activity in non-small-cell lung cancer, esophageal, and head and neck carcinoma; it appears to have little or no therapeutic value in renal cell cancer. Toxicities have been manageable, and included mild nausea and vomiting, diarrhea, mucositis, and myelosuppression. The dose-limiting toxicity, seen most frequently in those patients with impaired renal function, was lethargy and fatigue. MGBG has demonstrated activity in lymphomas, lung, esophageal, and head and neck cancer. Further trials of this agent are indicated, both alone and in combination.
Insights
Methylglyoxal-bis(guanylhydrazone) (MGBG) shows significant antineoplastic activity in lymphomas and modest effects in lung, esophageal, and head and neck cancers. Further trials are recommended for this promising anti-cancer agent.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Methylglyoxal-bis(guanylhydrazone) (MGBG) is an antineoplastic agent evaluated in a broad phase II clinical trial.
- Previous studies have investigated MGBG across various cancer types, including renal cell carcinoma, lymphomas, and non-small-cell lung cancer.
Purpose of the Study:
- To assess the efficacy and toxicity of MGBG in patients with various solid tumors and lymphomas.
- To determine the therapeutic potential of MGBG in different cancer types.
Main Methods:
- A broad phase II clinical trial was conducted involving patients with esophageal cancer, head and neck cancer, lymphomas, and other solid tumors.
- Patient response, including partial remissions (PR), and adverse events were systematically recorded.
Main Results:
- MGBG demonstrated significant antineoplastic activity in lymphomas, with 40% of heavily pretreated patients achieving partial remissions.
- Modest activity was observed in non-small-cell lung cancer, esophageal, and head and neck carcinomas.
- MGBG showed limited efficacy in renal cell carcinoma. Manageable toxicities included nausea, vomiting, diarrhea, mucositis, and myelosuppression. Lethargy and fatigue were dose-limiting toxicities, particularly in patients with renal impairment.
Conclusions:
- MGBG exhibits notable activity against lymphomas and shows promise in lung, esophageal, and head and neck cancers.
- Further clinical trials investigating MGBG, both as a monotherapy and in combination regimens, are warranted.
- MGBG appears to have limited therapeutic value in renal cell carcinoma.